Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06142669

EVOLUTION® Revision STEMMED CS Post Market Clinical Follow-up Study Protocol

MicroPort (MPO) is conducting this PMCF study to evaluate the safety and effectiveness of its EVOLUTION® Revision Tibial System and EVOLUTION® Revision STEMMED CS Femur with the EVOLUTION® MP CS Tibial Insert. This type of study is required by regulatory authorities for all devices that have been approved in Europe to evaluate the medium and long-term clinical evidence.

Recruiting

Interested in participating?

Request Info

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Gaetano Pini Orthopedic Institute

Milan, Piazza C. Ferrari 1 20122 Milan, Italy

Location status: Recruiting

Location contact

Pietro Randelli, Prof

CONTACT

[email protected]

+39-335-5292-622

Pietro Randelli, Prof

PRINCIPAL_INVESTIGATOR

About this study

The primary objective of this study is to estimate individual component survivorship for tibial base, femoral component, and tibial insert at specified intervals out to 10 years follow-up.

The secondary objectives include:

  • Determine the cumulative incidence of individual component revision at specified intervals out to 10 years follow-up;
  • Characterize functional scores for subjects, as assessed by KOOS Scores and EQ-5D-5L Scores, out to 10 years follow-up;
  • To assess subject satisfaction with their TKA procedure using the Forgotten Joint Score and a Satisfaction Survey;
  • To assess the presence, zone, and the size of radiolucencies surrounding implanted components out to 10 years follow-up;
  • To assess safety and characterize protocol defined adverse events and adverse device effects.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Has previously undergone or currently has been determined to undergo a revision knee arthroplasty that requires implantation of the components under study (EVOLUTION® Revision Tibial System and EVOLUTION® STEMMED CS Femur with the EVOLUTION® MP CS Tibial Insert)
  • Decision to perform the study index surgery with the required study components is pre-determined regardless of the research;
  • Previously implanted subjects must be enrolled within 3 years (+ 6 months) of their study index surgery
  • Willing to voluntarily sign the informed consent form
  • Willing and able to comply with the protocol, able to read and complete the required forms, and willing and able to adhere to the requirements of the protocol through the 10-year postoperative follow-up visit.

Exclusion criteria

  • Skeletally immature (less than 21 years of age) at time of implantation
  • Has or had an overt infection at the time of implantation
  • Has or had inadequate neuromuscular status (e.g., prior paralysis, fusion, and/or inadequate abductor strength), poor bone stock, poor skin coverage around the joint which would make the procedure unjustifiable
  • Currently enrolled in another clinical investigation which could affect the endpoints of this protocol
  • Has or had documented substance abuse issues
  • Has or had an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study
  • Currently incarcerated or has impending incarceration
  • Has a medical condition, as judged by the Investigator, that would interfere with the subject's ability to comply with the requirements of the protocol

Treatment and study plan

EVOLUTION® Revision Tibial System and EVOLUTION® Stemmed CS Femur with the EVOLUTION® MP CS Tibial Insert

Device

Primary knee arthroplasty or a revision knee that requires a revision procedure.

Primary outcomes

  1. The proportion of EVOLUTION® Revision Tibial Base components survivorship out to 10 years.

    Time frame: up to 10 years

    Percentage of knees survived with no revision or replacement at 10-year

  2. The proportion of EVOLUTION® STEMMED CS Femoral components survivorship out to 10 years.

    Time frame: up to 10 years

    Percentage of knees survived with no revision or replacement at 10-year

  3. The proportion of EVOLUTION® MP CS tibial inserts survivorship out to 10 years.

    Time frame: up to 10 years

    Percentage of knees survived with no revision or replacement at 10-year

Secondary outcomes

  1. Functional Scores

    Time frame: Year 1,Year 3, Year 5, Year 7, and Year 10

    To assess functional scores utilizing Knee Injury and Osteoarthritis Outcome Score (KOOS Scores) out to 10 years follow-up.

  2. Functional Scores

    Time frame: Year 1,Year 3, Year 5, Year 7, and Year 10

    To assess subject satisfaction with their Total Knee Arthroplasty (TKA) procedure utilizing the Forgotten Joint Score (FJS) at specified intervals out to 10 years follow-up.

  3. Functional Scores

    Time frame: Year 1,Year 3, Year 5, Year 7, and Year 10

    To assess functional scores utilizing EQ-5D-5L at specified intervals out to 10 years follow-up.

  4. Subject Satisfaction

    Time frame: Year 1,Year 3, Year 5, Year 7, and Year 10

    To assess subject satisfaction with their TKA procedure via the Satisfaction Survey at specified intervals out to 10 years follow-up.

  5. Radiolucencies

    Time frame: Year 1,Year 3, Year 5, Year 7, and Year 10

    To assess the presence of radiolucencies surrounding the implanted components at specified intervals out to 10 years follow-up.

  6. To assess subject safety: Adverse Events o Adverse Events related to study device or the index surgical procedure

    Time frame: Year 1,Year 3, Year 5, Year 7, and Year 10

    To assess safety and characterize protocol defined adverse events and adverse device effects.

  7. Incidence of component revision

    Time frame: Year 1,Year 3, Year 5, Year 7, and Year 10

    Determine the cumulative incidence of individual component revision at specified intervals out to 10 years follow-up.

Study contacts

Contact information is provided by the study sponsor or research team.

JoAnna-Marie N Becker, BS

CONTACT

[email protected]

+1 901 290 5280

Pietro Randelli, Prof

CONTACT

[email protected]

+39-335-5292-622

Sponsors and collaborators

Lead sponsor

MicroPort Orthopedics Inc.

Industry

Registry information

Official study title

Post Market Clinical Follow-Up Study for EVOLUTION® Revision Tibial System and EVOLUTION® Stemmed CS Femur With the EVOLUTION® MP CS Tibial Insert

Important dates

Study start
2023
Primary completion
2036
Study completion
2036
First posted
Nov 21, 2023
Registry last updated
Jan 22, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.